Alphatec (US:ATEC)2026-01-12 14:10Revenue Growth - Full-year 2025 total revenue increased by approximately 25% to around $764 million[2] - Surgical revenue for full-year 2025 grew by 26% to approximately $687 million, driven by a 24% increase in surgical volume[2] - The company expects full-year 2026 total revenue of $890 million, reflecting a growth of approximately 17% compared to 2025[7] - Full-year 2025 adjusted EBITDA guidance is reaffirmed at $91 million, indicating strong revenue growth leverage[3] Financial Performance - Adjusted EBITDA for full-year 2026 is anticipated to be around $130 million, contributing to an expected free cash flow of $20 million[7] - The company reported a cash balance of approximately $161 million as of December 31, 2025, with expected fourth-quarter free cash flow between $6 million and $8 million[3] Strategic Initiatives - The acquisition of exclusive U.S. distribution rights for Theradaptive's OsteoAdapt® is expected to enhance procedural offerings and address market concentration issues[6] - The company is positioned to shape the future of spine care with a scalable infrastructure and multiple growth catalysts ahead[4] Future Reporting - The company will report detailed financial results for Q4 and full-year 2025 on February 24, 2026[9] Operational Metrics - The company achieved an average revenue per surgical procedure growth of 2% in 2025[2]